



ClC-K chloride channels: emerging pathophysiology of Bartter syndrome type 3

Olga Andrini, Mathilde Keck, Rodolfo Briones, Stéphane Lourdel, Rosa Vargas-Poussou, Jacques Teulon

► To cite this version:

Olga Andrini, Mathilde Keck, Rodolfo Briones, Stéphane Lourdel, Rosa Vargas-Poussou, et al.. ClC-K chloride channels: emerging pathophysiology of Bartter syndrome type 3. *AJP Renal Physiology*, 2015, 308 (12), pp.F1324-F1334. 10.1152/ajprenal.00004.2015 . hal-02453172

HAL Id: hal-02453172

<https://hal.sorbonne-universite.fr/hal-02453172>

Submitted on 24 Jan 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

CIC-K chloride channels: Emerging pathophysiology of Bartter syndrome type 3

Olga Andrini^{1,2}, Mathilde Keck^{1,2}, Rodolfo Briones³, Stéphane Lourdel^{1,2}, Rosa Vargas-Poussou^{4,5} and Jacques Teulon^{1,2}.

¹UPMC Université Paris 06, UMR_S 1138, Team 3, F-75006, Paris, France; ²INSERM, UMR_S 872, Paris, France; ³Department of Theoretical and Computational Biophysics, Max-Planck Institute for Biophysical Chemistry, 37077 Göttingen, Germany; ⁴Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Département de Génétique F-75908, Paris, France; ⁵Université Paris-Descartes, Faculté de Médecine, F-75006, Paris, France.

Running Head: Pathophysiology Bartter syndrome type 3

Address for correspondence:

Jacques Teulon,
UMR_S 1138, team 3, 15 rue de l'Ecole de Médecine, 75720 Paris Cedex 06, France
Phone: 33 144 27 50 50 ; fax: 33 1 46 33 41 72, E-mail: jacques.teulon@upmc.fr

21 **Abstract**

22 The mutations in *CLCNKB* gene encoding the ClC-Kb chloride channel are responsible for
23 Bartter syndrome type 3, one of the 4 variants of Bartter syndrome in the genetically-based
24 nomenclature. All forms of Bartter syndrome are characterized by hypokalaemia, metabolic alkalosis
25 and secondary hyperaldosteronism but Bartter syndrome type 3 has the most heterogeneous
26 presentation, extending from severe to very mild. A relatively large number of *CLCNKB* mutations
27 have been reported, including gene deletions and nonsense or missense mutations. However, only
28 20 *CLCNKB* mutations have been functionally analyzed, due to technical difficulties regarding ClC-Kb
29 functional expression in heterologous systems. This review provides an overview of recent progress
30 in the functional consequences of *CLCNKB* mutations on ClC-Kb chloride channel activity. It has been
31 observed that: 1) all ClC-Kb mutants have an impaired expression at the membrane; and 2) a
32 minority of the mutants combines reduced membrane expression with altered pH-dependent
33 channel gating. Although further investigation is needed to fully characterize disease pathogenesis,
34 Bartter syndrome type 3 probably belongs to the large family of conformational diseases, in which
35 the mutations destabilize channel structure, inducing ClC-Kb retention in the endoplasmic reticulum
36 and accelerated channel degradation.

37

38 **Keywords:** Bartter syndrome, CLC family of chloride transporters and channels, chloride
39 channel.

40

41
42

43 **Bartter syndrome**

44 Bartter syndrome is an autosomal recessive salt wasting tubulopathy, characterized by
45 hypokalaemia, metabolic alkalosis and secondary hyperaldosteronism with normal-to-low blood
46 pressure. Clinically, two variants are distinguished: antenatal Bartter syndrome (aBS) and classic
47 Bartter syndrome (cBS)(8, 39, 48, 80, 81, 97). The aBS is a severe form leading to polyhydramnios due
48 to polyuria *in utero*, and premature birth. It is often complicated by dehydration episodes in the
49 neonatal period and growth retardation. Nearly all patients present with hypercalciuria and
50 medullary nephrocalcinosis. An elevated PGE2 production contributes to aggravate the course of the
51 disease, a fact which prompted the alternate denomination of hyperprostaglandin E syndrome (81).
52 The aBS derives from mutations of the genes encoding the $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransporter and the Kir1.1 K^+
53 channel (ROMK), *SLC12A1* and *KCNJ1*, respectively (84-86). In the genetically-based nomenclature
54 they correspond to Bartter syndrome type 1 (OMIM #601678) and 2 (OMIM #241200). The cBS is
55 usually diagnosed in early childhood. Failure to thrive is usually accompanied by low chloremia and
56 severe hypokalemic alkalosis (8, 39, 81), polyuria and hypercalciuria being less frequent. The cBS is
57 due to mutations of the *CLCNKB* gene encoding ClC-Kb Cl^- channel (83). This corresponds to Bartter
58 syndrome type 3 in the genetically-based nomenclature (OMIM #607364). There is a large
59 heterogeneity in Bartter syndrome type 3 presentation, extending from aBS to Gitelman syndrome
60 (8, 38, 48). Gitelman syndrome is classically a defect in distal convoluted tubule (DCT) transport due
61 to mutations in the *SLC12A3* encoding the $\text{Na}^+\text{-Cl}^-$ cotransporter (37, 97), but some patients carrying
62 *CLCNKB* mutations have quite a similar phenotype, exhibiting hypomagnesemia, hypo- or normo-
63 calciuria, insensitivity to thiazide administration and absence of polyuria (8, 38).

64 The population of chloride channels in the renal tubule includes two additional players: ClC-
65 Ka, a Cl^- channel α -subunit of the same family as ClC-Kb, which is encoded by the *CLCNKA* gene, and
66 the regulatory β -subunit Barttin encoded by the *BSND* gene. A fourth variant of the Bartter
67 syndrome, the aBS with sensorineural hearing loss (SNHL) is caused either by *BSND* mutations [OMIM

68 #602522 (7)(see (21) for review)], or by simultaneous mutations in the *CLCNKB* and *CLCNKA* genes
69 [OMIM#613090, (69, 77)].

70 **CIC-K chloride channels**

71 CIC-Ka and CIC-Kb (CIC-K1 and CIC-K2 in rat and mouse) chloride channels were cloned in the
72 90s by the groups of Uchida and Jentsch (44, 90, 95). They comprise 687 amino acids and are
73 probably present as homodimers at the plasma membrane. Except for the rat CIC-K1 (95), functional
74 expression of the CIC-Ks was unsuccessful until the cloning of Barttin in 2001(7) when functional
75 studies established that Barttin was a CIC-K regulatory subunit (19, 100). The electrophysiological
76 properties of the CIC-Ks remain imperfectly known. CIC-Ka and rat and mouse CIC-K1 have been
77 studied at the single-channel level and show conductances of 25 to 45 pS (3, 24, 43, 74) while it has
78 not been possible until now to measure the unit conductance of CIC-Kb / CIC-K2. The only regulatory
79 properties identified so far are the inhibition at acid extracellular pH and the activation at high
80 extracellular calcium (19, 30, 31, 100). In addition, a block at very basic 9-11 pH has also been
81 reported (32). The physiological impact of these regulations remains uncertain. On the one hand,
82 CIC-Ka and CIC-Kb are relatively insensitive to calcium between 0.5 and 2 mM (3, 33, 43), which
83 makes it unlikely that calcium variations in the physiological range affect channel activity. On the
84 other hand, pH changes such as those experienced during acidosis or alkalosis might affect CIC-Kb
85 (pKa=7.9, (3)) and CIC-Ka (pKa = 7.3, (33)).

86 At the protein level, the degree of identity between the two isoforms is slightly higher within
87 (about 80-90%) than across (human vs. rodent) species (44, 89, 94). This makes it impossible to
88 determine homologs between species on the basis of sequence comparison. However, the diverse
89 available data have led to the consensus that rodent CIC-K1 and human CIC-Ka, on the one hand, and
90 rodent CIC-K2 and human CIC-Kb, on the other hand, are functional orthologs (89, 94).

91 Collectively, the two CIC-K proteins are present all along the distal nephron, from the thin
92 ascending limb to the collecting duct (in the intercalated cells), but not in the proximal tubule (19).
93 This is confirmed by Barttin antibody staining the same segments of the renal tubule (19). The

expression is restricted to the basolateral membrane (19, 89) except for the thin ascending limb (tAL) where CIC-K is present on both apical and basolateral membranes (96). The differential distribution of the two channels along the renal tubule has been difficult to ascertain in the absence of isoform-specific antibodies. However, immunocytochemistry performed on the kidneys of CIC-K1^{-/-} mice demonstrated that CIC-K1 was the only isoform present in the tAL (45) and that CIC-K2 was present in the thick ascending limb (TAL), DCT and the intercalated cells of cortical collecting duct (CCD) (45). Patch-clamp experiments have also given some insight into the localization of the two channels: a recent study has demonstrated the correspondence between 45-pS chloride channel in the mouse TAL (70) and recombinant mouse CIC-K1 (50). Thus, a second 10-pS channel, activated by external calcium and at alkaline pH, which is expressed in the DCT and intercalated cells of the CNT and CCD, probably represents CIC-K2 (56, 66, 67, 70, 91). Together with results obtained with RT-PCR on rat renal segments (19, 44-46, 49, 96, 100), a consensus pattern emerges, which places CIC-K1 in the tAL and TAL, and CIC-K2 in the TAL, DCT and the intercalated cells of the CNT and CD (Fig. 1a).

A major insight in CIC-Ka function was provided by Uchida and associates (1, 54, 61) who analyzed the consequences of CLCNK1 deletion in the mouse. Matsumura et al (61) observed no hypokalaemic alkalosis in *Clcnk1*^{-/-} mice, which would have been suggestive of Bartter syndrome, but polyuria (x5 compared to wild type), associated with low urine osmolality (3-fold lower than WT), was dramatic. Furthermore, *Clcnk1*^{-/-} mice failed to concentrate urine after 24-h water deprivation or intraperitoneal injection of dDAVP (~2500 mOsm/kg H₂O in WTmice vs. ~850 mOsm/kg H₂O in *Clcnk1*^{-/-} mice) (61). A follow-up study showed that the fractional excretion of sodium, chloride and urea, as well as the total osmolar clearance, were not altered in *Clcnk1*^{-/-} mice (1). Thus, polyuria is due to water diuresis, not osmotic diuresis. In addition, the urea and NaCl contents in the interstitium of the inner medulla were decreased by a factor 2 in *Clcnk1*^{-/-} as compared to *Clcnk1*^{+/+} mice (1). Furthermore, no Cl⁻ conductance was detected in microperfused tALs of CIC-K1^{-/-} mice (54, 61). Thus, the loss-of-function of CIC-K1 causes nephrogenic diabetes insipidus by impairing the countercurrent system in the inner medulla (1). As pointed out by Matsumura et al (61), it is doubtful

that CLCNKA deletion would cause a similar pathology in humans, who have a less developed inner medulla.

The results of Uchida's group confirm that ClC-K1 is mostly present in the thin ascending limb. Thus, although no *Clcnk2*^{-/-} mouse line is yet available, we may speculate that ClC-K2 has a predominant role in the other parts of the mouse renal tubule. Ion transport models for the TAL and DCT (Fig 1b, c) involve two distinct Na⁺-Cl⁻ cotransporters, NKCC2 and NCC, respectively, at the apical membrane. The exit of chloride on the basolateral side is dependent on Cl⁻ channels (18, 39, 79). Basolateral Cl⁻ channels are also important for ion transport in the intercalated cells (18, 79, 88) (Fig1d). Classically, the β intercalated cells participate in bicarbonate secretion but Eladari and Chambrey (11, 18, 52) recently discovered a novel, neutral pathway for NaCl absorption in these cells (Fig 1d), which includes a Cl⁻ conductance at the basolateral side (18, 79, 88). The α intercalated cells (Fig 1d) participate in acid-base balance by secreting protons *via* the V-type H⁺ ATPase at the apical membrane and the AE1 HCO₃⁻/Cl⁻ exchanger at the basolateral membrane. Basolateral Cl⁻ channels optimize H⁺ secretion by recycling Cl⁻, thus facilitating the functioning of the AE1 exchanger (88). In summary, ClC-K2 is expected to play a key role in Cl⁻ absorption in the DCT, CNT/CCD and to a lower extent in the TAL, where ClC-K1 is present (50, 70). There has been yet no patch-clamp study of ClC-K chloride channels in the α intercalated cells, letting open the possibility that the two channels cooperate at this site.

Structure of the ClC-K chloride channels

Renal chloride channels belong to the channel subgroup of the ClC family of chloride channels and transporters, which also includes ClC-1 and ClC-2 (21, 42, 93). The structure of this protein family was revealed in 2002 with the crystallization of two bacterial Cl⁻/H⁺ exchangers from *S. typhimurium* and the *E. coli* (16). Each monomer is defined by 18 α-helices (from A to R) with an antiparallel structure, meaning that two structurally related halves (α-helices A to I and J to R, respectively) span the membrane with an opposite orientation (16). The ClC proteins are functional dimers constituted by two independent permeation pathways called protopores (see Fig. 2). The protopore, localized

between the two structurally related halves of the ClC monomer, is formed by an anion-selective filter between two aqueous vestibules comprising three Cl⁻-binding sites. The binding sites are located close to the extracellular side (S_{ext}), in the central region of the protein (S_{cen}) and close to the intracellular side (S_{in}) (17). These are formed by the N-termini of α -helices D and F in the first half of the monomer and the N-termini of α -helices N and R in the second half of the monomer. In ClC-0, ClC-1 and ClC-2 but not ClC-K, the access to each protopore is regulated *via* one opening / closing mechanism called *fast*, or “glutamate” gate. The structural determinant of this gating consists of an external glutamate (E148 in *E. coli*, ec-ClC), the protonation/deprotonation of which is directly implicated in gating (17, 64). In addition, the two protopores can be opened / closed simultaneously by the so called *common*, or *slow* gate (12, 72). This second mechanism is particularly important for the renal ClC-Ks that lack the characteristic “glutamate” responsible for protopore gating in the others ClC proteins (17).

Eukaryotic ClC proteins, including ClC-Ks, have a large cytoplasmic C-terminus domain constituted by a linker sequence connecting α -helix R to two cystathione- β -syntase domains (CBSs) [see Fig. 2]. The crystal structure of human CBS of ClC-5 (63) and ClC-Ka (58) reveals a dimeric interaction between two ClC protein C-terminal domains (59), likely to be conserved among the eukaryotic ClC (62). Several studies reported a regulatory role of binding of adenine nucleotides to CBS domains in ClC-1, ClC-2 and ClC-5 (65, 92, 105). This part of the protein is known to be involved in the regulation of the common gating (9, 20). A similar role has yet to be demonstrated for the ClC-Ks.

As noted above, the ClC-K currents recorded in over-expression systems are inhibited at acid pH and activated by an increase of $[Ca^{2+}]_{ext}$ (19, 30, 31, 100). A detailed screening of acidic amino-acid residues led to the identification of two critical amino-acids (E261 and D278, localized in the extracellular loop between α -helices I and J), which form the putative extracellular Ca^{2+} -binding site (31). A histidine residue on position 497 at the beginning of α -helix Q is responsible for the H⁺-induced block (30) [Fig. 2].

***CLCNKB* mutations in Bartter syndrome**

Since the pioneering work of Simon et al. identifying mutations in the *CLCNKB* gene as a cause of Bartter syndrome type 3 (83), a number of publications have reported pathogenic mutations (3, 8, 26, 43, 48, 51, 76, 83, 102, 103). As a whole, according to the Human Gene Mutation Database (free access HGMD database, Biobase International, www.hgmd.cf.ac.uk), more than 54 mutations have been described, including complex rearrangements, large and small deletions, small insertions, nonsense or missense mutations and splice site mutations. One characteristic feature of the disease is the frequent occurrence of total *CLCNKB* gene deletion (8, 29, 38, 48, 83).

The 50 point mutations (missense and nonsense) illustrated in Fig. 1 and summarized in Table 1 are distributed all along the protein with no clear hotspots. Several mutations are located close to several parts of the selectivity filter, in C-D linker and α -helix D (3 mutations), E-F linker and α -helix F (2 mutations) and α -helix N (8 mutations), respectively. By contrast, no mutations were reported in the vicinity of H^+ and Ca^{2+} binding sites. Altogether, 60% mutations are located on α -helices, 20% in helix linkers and 20% in the cytoplasmic part of the protein. About 16 homozygous mutations have been found in patients (A77P, L81P, T115P, P124L, G164C, V170M, A204T, G246R, S297R, R351W, H357Q, G424E, R438H, K560M, R595X, W610X). A few mutations such as A204T (29, 76, 83), P124L (3, 5, 43, 48, 83), R438H (3, 5, 43, 48, 83) and W610X (14, 51, 68) have been reported independently by several authors. In particular, A204T, a founder mutation in Spain, is the prevalent mutation in this country (28). W610X is the most common mutations in Korea (51).

Functional consequences of *CLCNKB* mutations

Only 20 *CLCNKB* mutations have been functionally analyzed. This low figure is mainly due to technical problems regarding ClC-Kb functional expression. Current recording of ClC-Kb in *X. laevis* oocytes or cultured cells has remained difficult even after the discovery of the Barttin regulatory subunit: ClC-Kb levels of current are 5-fold lower than those elicited by ClC-Ka (36, 43). An additional, specific problem concerns Western blotting of the ClC-K protein: over-expressed ClC-K proteins tend

to form stable aggregates so that the band corresponding to the monomeric protein is often hardly visible [(10, 43, 100, 101) but see (36)].

Before the discovery of Barttin, Waldegger et al. (101) succeeded in recording chloride currents from a chimeric human ClC-Kb/rat ClC-K1 construct [ClC-Kb (c)] and analyzed a selection of mutations reported by Simon et al. (83) in *X. laevis* oocytes using two-electrode voltage-clamp: P124L, A204T, A349D and R438C abolished ClC-Kb (c) current while Y432H dramatically reduced it, by at least 4 fold. Obviously, a limit of this interesting study lies in the use of chimeric channels, as it is difficult to anticipate how the presence of rat ClC-K1 stretches in the ClC-Kb protein might influence the observed effects. Soon afterwards, Estevez et al. (19) recorded for the first time ClC-K/Barttin complexes in *X. laevis* oocytes. They tested several of the mutations reported by Simon et al and Konrad et al (48, 83) by co-injecting mRNA for several ClC-Kb mutants with Y98A-mutant Barttin in order to increase surface expression of the channel complex. Overall A349D and R438C mutations totally abolished currents, as in the abovementioned study, while P124L, A204T, R538P and K560M mutations decreased the currents by 60-80%. More recently, Yu et al (102) analyzed R30X, A210V and R351W mutations by the same methods. As expected, R30X mutant generated no current; A210V and R351W currents were reduced by 53 and 39%, respectively. Overall, all these mutations (except A210V and R351W) reduced channel currents by more than 60% (19, 102).

Our group has recently investigated 8 novel *CLCNKB* mutations (L81P, R92W, G120R, V170M, G246R, R351P, G424E and L439P) (3, 43). We also selected some published mutations to gain a deeper understanding of the molecular defect behind the development of Bartter syndrome type III (T115P, P124L, L139P and R438H) (8, 48, 83, 103). In these studies, we co-expressed mutant ClC-Kb proteins with wild-type Barttin in *X. laevis* oocytes or HEK293 cells. The currents carried by the ClC-Kb mutants were reduced to different extents. For nearly half of the mutants (3, 43), no current was detected (T115P, G246R, G424E, R438H and L439P). Four mutants showed 50-70% residual activity (R92W, P124L, V170M, R351P), and two had a low activity around 20-40% (L81P, G120R) (3, 43).

Note that in our hands, P124L generated a noticeable current (40%) while lower currents (0-20%) were detected in previous studies (48, 85).

Surface expression varied from 0 to 85% when compared to WT ClC-Kb and was proportional to current level, indicating that the primary defect shown by mutants concerns the number of channel units in the membrane (3, 43). For mutants generating sufficient current, we evaluated unit conductance (R92W, R351P), anion selectivity (L81P, R92W, V170M and R351P), and pH- and Ca^{2+} -sensitivity (L80P, R92W, R351P, P124L and V170M) (3, 43). There was no change in conductance, selectivity or regulation except for two mutants (P124L, V170M) that displayed dramatic alteration in pH-sensitivity (see below). These results go along with the hypothesis that the primary defect induced by mutations is generally an alteration in surface expression of the channel.

Altogether, among the 20 mutations analyzed for the total current, 40% do not show any detectable activity (T115P, G246R, A349D, G424E, G424R, R438C, R438H and L439P), 40% maintain more than 50% activity (R92W, G120R, P124L, V170M, A210V, R351P, R351W and K560M) and 20% have a smaller activity around 20-30% (L81P, L139P, A204T and R538P). Total protein abundance (considering bands corresponding to monomeric and dimeric proteins) was assayed in HEK293 cells for a minority of mutants (43). Protein abundance was clearly reduced for those mutants that showed no current and no surface expression (G246R, G424E, R438H and L439P). This strongly suggests that the produced transcript is not stable in the expression system. Protein abundance was not reduced for mutants showing more than 50% activity (R92W and R351P) nor for one mutant with 20-30% activity (L81P). This suggests that the stability of the protein (for instance, accelerated retrieval from the membrane) in the membrane could be decreased.

Mutations that alter regulation/conduction appear to be predominant in myotonia caused by mutations in the *CLCN1* gene: ClC-1 is a voltage-dependent channel, which is activated by depolarization; many mutations profoundly shift voltage dependence towards more positive voltages (71, 73) or even convert ClC-1 to an inwardly-rectifying channel (22, 104). By contrast, mutations altering channel gating are not frequent in Bartter disease type 3. We have evaluated pH- and Ca^{2+} -

sensitivity for 6 CIC-Kb mutants and found alterations in only 2 (3, 43), while studies by others detected 2 additional mutants showing some kind of altered regulation. Maduke et al (59) reported that R538P mutation totally abolished sensitivity to Ca^{2+} . This is associated with a clear reduction in current (19). According to the authors, the arginine 538 being located in the cytoplasm after helix R, the lack of sensitivity to Ca^{2+} implies a long distance effect from the cytoplasmic side of the protein to its extracellular side (59). Similar Ca^{2+} -independence was reported by Yu et al (102) for R351W mutation (at the outer aspect of the protein in K-L linker), which was also associated with 60% decrease in current.

In our hands, two mutations (V170M and P124L) dramatically altered pH and Ca^{2+} sensitivity (3). The curve of H^+ -dependent inhibition shifted by about 1.5 pH units towards more acid values for V170M and P124L mutants as compared to WT CIC-Kb (pK_H : 6.0 for V170M and 6.1 for P124L vs. 7.6 for WT). Our results suggest that these mutations do not alter directly the binding-site of H^+ but disrupt the gating function of the channel, thus indirectly affecting the sensitivity to pH_ext (3). As a direct consequence, the mutant CIC-Kb channels are maximally active at pH 7.4 while the activity of WT CIC-Kb at this pH is only 20% of its maximal activity. In addition, we observed that the mutants were completely independent of Ca^{2+} at pH 7.4, perhaps because they are maximally active at this pH (3). In parallel, there was a clear reduction in current and surface expression in the two mutants (3). Therefore, these mutations result in hyperactive channels, which tend to offset the functional impact of reduced expression at the membrane. The opposite mechanism might operate in the case of T481S CIC-Kb, a *CLCNKB* single-nucleotide polymorphism that has been linked to essential hypertension (41, 82). Jeck et al (40) showed that the 5-20-fold increase in CIC-Kb current induced by T481S mutation was associated with higher sensitivity to pH (lower activity at pH 7.4) and an increase in membrane channel expression, a mirror image of what is observed in Bartter syndrome for CIC-Kb mutants.

Alteration of functional motifs as a cause of Bartter syndrome

Several of the mutations that have been functionally analyzed are located around the selectivity filter. Three mutations in α -helix N (R438C, R438H, L439P) and one close to it (G424E) are associated with reduction in total protein abundance, absence of expression at the membrane and absence of current. Two mutations (P124L and V170M) alter channel regulation. These results strongly suggest that the selectivity filter is of paramount importance for structure stability and gating. The hyperactivity of P124L and V170M is puzzling when considered in the context of disease pathophysiology. As already mentioned, mutations of the *CLCN1* gene causing myotonia often result in gating alterations. However, these alterations always render the channel less active (71). Thus, it is currently difficult to appreciate whether the uncoupling of channel activity from pH- and Ca^{2+} -dependent gating is a co-incidental side-effect of the mutations or whether these mutations alter yet unidentified regulators of channel activity.

By contrast, the available data provides little information about the functional effects of *CLCNKB* mutations in two other regions: α -helices B and J (8 mutations), which interact with Barttin, and CBS domains (7 mutations). The CBS domains might be particularly critical for channel function. They participate in ClC *common* gating (20, 25), likely *by* sensing intracellular metabolites (35). They also participate in channel trafficking and targeting to the plasma membrane. The partial deletion of the cytoplasmic domain leads to a retention of ClC-0 and ClC-1 proteins into the ER (20, 34, 57, 78). The only CBS1-located mutation that has been functionally characterized in over-expression systems (K560M) reduces ClC-Kb current to 25% of control (19).

The interface between the two monomers, mainly composed of α -helices H, I, P and Q, is potentially another critical region. In the case of Dent's disease, an X-linked hereditary disease due to mutations in the *CLCN5* gene encoding the Cl^-/H^+ exchanger ClC-5, about 60% of the mutations are located at the dimer interface (55). These mutations either result in ER retention or channel dysfunction (55). Mutations at the same location are also frequent in *CLCN7* gene causing osteopetrosis, or in *CLCN1* gene, where they modify channel gating (71). Unexpectedly, only 3 mutations have been found at the dimer interface in Bartter disease: P216L (51) and A242E (5),

which have not been functionally investigated and G246R which shows no current, no surface expression and reduced protein abundance (43). The latter result suggests a destabilization of the protein.

Obviously, further experiments focusing on surface channel expression and sub-cellular distribution would be necessary in the future to investigate the functional consequences of mutations in the CBS region, in the α -helices interacting with Barttin and at the dimer interface.

Phenotype-genotype relationship

The first papers reporting mutations in the *CLCNKB* gene causing Bartter syndrome type 3 already mentioned that the severity of the disease was highly variable (38, 48, 83). In particular, whole gene deletion, which is frequent in this disease, may cause aBS or cBS (38, 48, 83). This is also the case for A204T and R438H mutations (29, 76, 103). R438H mutation results in a non-functioning channel (43), A204T reduces current to 0-25% of control (48, 83). In particular, Zelikovic et al (103) showed that patients carrying the mutation R438H within one same large family could present with mild or severe symptoms. Especially in the case of *CLCNKB* gene deletion, the variable severity of the disease suggests that ClC-Ka Cl⁻ channel, K⁺-Cl⁻ cotransporter (8) or additional Cl⁻ channels (60) might be expressed in the TAL in a variable fashion and compensate for the loss of function of ClC-Kb in some patients. In the case of point mutations, one alternative possibility would be that the defect being due to conformational destabilization has variable impact depending on the individual.

The 8 patients homozygous for V170M, or compound heterozygous with another mutation (whole gene deletion or mutations resulting in the production of unstable mRNAs or truncated proteins) have a mild phenotype (3). It is likely that these patients mainly express V170M homodimers of this hyperactive channel with reduced expression at the membrane. This is also the case for one patient homozygous for P124L, but not for 2 other patients compound heterozygous for P124L and G465R (3). It will be interesting to observe whether more mutations of this type are detected in the future and whether they are associated with a mild presentation.

Conclusion

Overall, currently available data suggests that *CLCNKB* mutations might be arranged in two main classes: (i) mutations causing fully impaired (about 40% of the mutations) or reduced (about 60% of the mutations) channel expression at the membrane; (ii) mutations combining reduced channel surface expression with altered channel properties (about 20% of the total number of mutations analyzed).

It is clear that further investigation is needed to fully characterize the pathogenesis of Bartter disease type 3, which has been hampered by technical difficulties in the expression of this particular chloride channel. However, Bartter disease type 3 probably belongs to the large family of conformational diseases, in which the mutations destabilize channel structure, inducing retention in the endoplasmic reticulum and accelerated channel degradation. Accordingly, a classical approach to treatment would be to test the efficacy of adapted chaperons for enhancing ClC-Kb surface expression. An approach of this type has been recently performed with some success on W610X ClC-Kb mutants in MDCK cells using an aminoglycoside derivative (14). This long-term strategy might be helpful for those patients who present with a severe form of Bartter syndrome type 3.

At the end of this review dedicated to the pathophysiology of Bartter syndrome, it is worth reminding that one *CLCNKB* single-nucleotide polymorphism (T481S) has been linked to essential hypertension (41, 82). Although the association with hypertension was not replicated by some studies (23, 47, 87), the idea that ClC-Kb might be functionally important for long-term control of blood pressure remains attractive, and keeps in line with recent findings pointing out the importance of chloride in blood pressure regulation (18). In addition, several *CLCNKA* single-nucleotide polymorphisms have been associated with salt-sensitive hypertension (4) or heart failure (10). Altogether, these various reports suggest that the pathophysiological impact of ClC-Kb and ClC-Ka on NaCl balance might be not restricted to Bartter syndrome.

351 **Grants**

352 This work was supported by grants from French Research National Agency (ANR BLAN 2010-111201,
353 ANR-14-CE12-0013-02), French Kidney Foundation and ECOS-sud (C14-S01). The work of R. Briones
354 was supported by a grant from DFG (SFB803).

355
356 **Acknowledgments**

357 We thank the patients, their families, and the nephrologists from the French tubulopathy
358 network. The English text was edited by Charlotte Sumida. The present address of Mathilde Keck is
359 UMR INSERM 1166 ICAN, 91 boulevard de l'Hôpital, 75013 PARIS, France

360 **Conflict of interest**

361 None

362

References

1. **Akizuki N, Uchida S, Sasaki S, and Marumo F.** Impaired solute accumulation in inner medulla of *Clcnk1*^{-/-} mice kidney. *Am J Physiol Renal Physiol* 280: F79-87, 2001.
2. **Al-Shibli A, Yusuf M, Abounajab I, and Willems PJ.** Mixed Bartter-Gitelman syndrome: an inbred family with a heterogeneous phenotype expression of a novel variant in the *CLCNKB* gene. *Springerplus* 3: 96, 2014.
3. **Andrini O, Keck M, L'Hoste S, Briones R, Mansour-Hendili L, Grand T, Sepulveda FV, Blanchard A, Lourdel S, Vargas-Poussou R, and Teulon J.** *CLCNKB* mutations causing mild Bartter syndrome profoundly alter the pH and Ca dependence of *ClC-Kb* channels. *Pflugers Arch* 2014.
4. **Barlassina C, Dal Fiume C, Lanzani C, Manunta P, Guffanti G, Ruello A, Bianchi G, Del Vecchio L, Macciardi F, and Cusi D.** Common genetic variants and haplotypes in renal *CLCNKA* gene are associated to salt-sensitive hypertension. *Hum Mol Genet* 16: 1630-1638, 2007.
5. **Bettinelli A, Borsa N, Bellantuono R, Syren ML, Calabrese R, Edefonti A, Komninos J, Santostefano M, Beccaria L, Pela I, Bianchetti MG, and Tedeschi S.** Patients with biallelic mutations in the chloride channel gene *CLCNKB*: long-term management and outcome. *Am J Kidney Dis* 49: 91-98, 2007.
6. **Bettinelli A, Borsa N, Syren ML, Mattiello C, Coviello D, Edefonti A, Giani M, Travi M, and Tedeschi S.** Simultaneous mutations in the *CLCNKB* and *SLC12A3* genes in two siblings with phenotypic heterogeneity in classic Bartter syndrome. *Pediatr Res* 58: 1269-1273, 2005.
7. **Birkenhager R, Otto E, Schurmann MJ, Vollmer M, Ruf EM, Maier-Lutz I, Beekmann F, Fekete A, Omran H, Feldmann D, Milford DV, Jeck N, Konrad M, Landau D, Knoers NV, Antignac C, Sudbrak R, Kispert A, and Hildebrandt F.** Mutation of *BSND* causes Bartter syndrome with sensorineural deafness and kidney failure. *Nat Genet* 29: 310-314, 2001.
8. **Brochard K, Boyer O, Blanchard A, Loirat C, Niaudet P, Macher MA, Deschenes G, Bensman A, Decramer S, Cochat P, Morin D, Broux F, Caillez M, Guyot C, Novo R, Jeunemaitre X, and Vargas-Poussou R.** Phenotype-genotype correlation in antenatal and neonatal variants of Bartter syndrome. *Nephrol Dial Transplant* 24: 1455-1464, 2009.
9. **Bykova EA, Zhang XD, Chen TY, and Zheng J.** Large movement in the C terminus of *CLC-0* chloride channel during slow gating. *Nat Struct Mol Biol* 13: 1115-1119, 2006.
10. **Cappola TP, Matkovich SJ, Wang W, van Booven D, Li M, Wang X, Qu L, Sweitzer NK, Fang JC, Reilly MP, Hakonarson H, Nerbonne JM, and Dorn GW, 2nd.** Loss-of-function DNA sequence variant in the *CLCNKA* chloride channel implicates the cardio-renal axis in interindividual heart failure risk variation. *Proc Natl Acad Sci U S A* 108: 2456-2461, 2011.
11. **Chambrey R, Kurth I, Peti-Peterdi J, Houillier P, Purkerson JM, Leviel F, Hentschke M, Zdebik AA, Schwartz GJ, Hubner CA, and Eladari D.** Renal intercalated cells are rather energized by a proton than a sodium pump. *Proc Natl Acad Sci U S A* 110: 7928-7933, 2013.
12. **Chen TY.** Structure and function of *clC* channels. *Annu Rev Physiol* 67: 809-839, 2005.
13. **Chiang WF, Lin SH, and Chan JS.** Hypokalemic paralysis in a middle-aged female with classic Bartter syndrome. *Clin Nephrol* 81: 146-150, 2012.
14. **Cho HY, Lee BH, and Cheong HI.** Translational read-through of a nonsense mutation causing Bartter syndrome. *J Korean Med Sci* 28: 821-826, 2013.
15. **Corpet F.** Multiple sequence alignment with hierarchical clustering. *Nucleic Acids Res* 16: 10881-10890, 1988.
16. **Dutzler R, Campbell EB, Cadene M, Chait BT, and MacKinnon R.** X-ray structure of a *ClC* chloride channel at 3.0 Å reveals the molecular basis of anion selectivity. *Nature* 415: 287-294, 2002.
17. **Dutzler R, Campbell EB, and MacKinnon R.** Gating the selectivity filter in *ClC* chloride channels. *Science* 300: 108-112, 2003.
18. **Eladari D, Chambrey R, Picard N, and Hadchouel J.** Electroneutral absorption of NaCl by the aldosterone-sensitive distal nephron: implication for normal electrolytes homeostasis and blood pressure regulation. *Cell Mol Life Sci* 71: 2879-2895, 2014.

19. **Estevez R, Boettger T, Stein V, Birkenhager R, Otto E, Hildebrandt F, and Jentsch TJ.** Barttin is a Cl⁻ channel beta-subunit crucial for renal Cl⁻ reabsorption and inner ear K⁺ secretion. *Nature* 414: 558-561, 2001.
20. **Estevez R, Pusch M, Ferrer-Costa C, Orozco M, and Jentsch TJ.** Functional and structural conservation of CBS domains from CLC chloride channels. *J Physiol* 557: 363-378, 2004.
21. **Fahlke C, and Fischer M.** Physiology and pathophysiology of CLC-K/barttin channels. *Front Physiol* 1: 3-12, 2010.
22. **Fahlke C, Rudel R, Mitrovic N, Zhou M, and George AL, Jr.** An aspartic acid residue important for voltage-dependent gating of human muscle chloride channels. *Neuron* 15: 463-472, 1995.
23. **Fava C, Montagnana M, Almgren P, Rosberg L, Guidi GC, Berglund G, and Melander O.** The functional variant of the CLC-Kb channel T481S is not associated with blood pressure or hypertension in Swedes. *J Hypertens* 25: 111-116, 2007.
24. **Fischer M, Janssen AG, and Fahlke C.** Barttin activates CLC-K channel function by modulating gating. *J Am Soc Nephrol* 21: 1281-1289, 2010.
25. **Fong P, Rehfeldt A, and Jentsch TJ.** Determinants of slow gating in CLC-0, the voltage-gated chloride channel of *Torpedo marmorata*. *Am J Physiol* 274: C966-973, 1998.
26. **Fukuyama S, Hiramatsu M, Akagi M, Higa M, and Ohta T.** Novel mutations of the chloride channel Kb gene in two Japanese patients clinically diagnosed as Bartter syndrome with hypocalciuria. *J Clin Endocrinol Metab* 89: 5847-5850, 2004.
27. **Fukuyama S, Okudaira S, Yamazato S, Yamazato M, and Ohta T.** Analysis of renal tubular electrolyte transporter genes in seven patients with hypokalemic metabolic alkalosis. *Kidney Int* 64: 808-816, 2003.
28. **Garcia-Nieto V, Flores C, Luis-Yanes MI, Gallego E, Villar J, and Claverie-Martin F.** Mutation G47R in the BSND gene causes Bartter syndrome with deafness in two Spanish families. *Pediatr Nephrol* 21: 643-648, 2006.
29. **Garcia Castano A, Perez de Nanclares G, Madariaga L, Aguirre M, Madrid A, Nadal I, Navarro M, Lucas E, Fijo J, Espino M, Espitaletta Z, Castano L, and Ariceta G.** Genetics of type III Bartter syndrome in Spain, proposed diagnostic algorithm. *PLoS One* 8: e74673, 2013.
30. **Gradogna A, Babini E, Picollo A, and Pusch M.** A regulatory calcium-binding site at the subunit interface of CLC-K kidney chloride channels. *J Gen Physiol* 136: 311-323, 2011.
31. **Gradogna A, Fenollar-Ferrer C, Forrest LR, and Pusch M.** Dissecting a regulatory calcium-binding site of CLC-K kidney chloride channels. *J Gen Physiol* 140: 681-696, 2012.
32. **Gradogna A, and Pusch M.** Alkaline pH block of CLC-K kidney chloride channels mediated by a pore lysine residue. *Biophys J* 105: 80-90, 2013.
33. **Gradogna A, and Pusch M.** Molecular Pharmacology of Kidney and Inner Ear CLC-K Chloride Channels. *Front Pharmacol* 1: 130, 2010.
34. **Hebeisen S, Biela A, Giese B, Muller-Newen G, Hidalgo P, and Fahlke C.** The role of the carboxyl terminus in CLC chloride channel function. *J Biol Chem* 279: 13140-13147, 2004.
35. **Ignoul S, and Eggermont J.** CBS domains: structure, function, and pathology in human proteins. *Am J Physiol Cell Physiol* 289: C1369-1378, 2005.
36. **Janssen AG, Scholl U, Domeyer C, Nothmann D, Leinenweber A, and Fahlke C.** Disease-causing dysfunctions of barttin in Bartter syndrome type IV. *J Am Soc Nephrol* 20: 145-153, 2009.
37. **Jeck N, Konrad M, Hess M, and Seyberth HW.** The diuretic- and Bartter-like salt-losing tubulopathies. *Nephrol Dial Transplant* 15 Suppl 6: 19-20, 2000.
38. **Jeck N, Konrad M, Peters M, Weber S, Bonzel KE, and Seyberth HW.** Mutations in the chloride channel gene, CLCNKB, leading to a mixed Bartter-Gitelman phenotype. *Pediatr Res* 48: 754-758, 2000.
39. **Jeck N, Schlingmann KP, Reinalter SC, Komhoff M, Peters M, Waldegger S, and Seyberth HW.** Salt handling in the distal nephron: lessons learned from inherited human disorders. *Am J Physiol Regul Integr Comp Physiol* 288: R782-795, 2005.

465 40. **Jeck N, Waldegger P, Doroszewicz J, Seyberth H, and Waldegger S.** A common sequence
466 variation of the CLCNKB gene strongly activates ClC-Kb chloride channel activity. *Kidney Int* 65: 190-
467 197, 2004.

468 41. **Jeck N, Waldegger S, Lampert A, Boehmer C, Waldegger P, Lang PA, Wissinger B, Friedrich
469 B, Risler T, Moehle R, Lang UE, Zill P, Bondy B, Schaeffeler E, Asante-Poku S, Seyberth H, Schwab M,
470 and Lang F.** Activating mutation of the renal epithelial chloride channel ClC-Kb predisposing to
471 hypertension. *Hypertension* 43: 1175-1181, 2004.

472 42. **Jentsch TJ.** ClC chloride channels and transporters: from genes to protein structure,
473 pathology and physiology. *Crit Rev Biochem Mol Biol* 43: 3-36, 2008.

474 43. **Keck M, Andrini O, Lahuna O, Burgos J, Cid LP, Sepulveda FV, L'Hoste S, Blanchard A,
475 Vargas-Poussou R, Lourdel S, and Teulon J.** Novel CLCNKB mutations causing Bartter syndrome
476 affect channel surface expression. *Hum Mutat* 34: 1269-1278
477 2013.

478 44. **Kieferle S, Fong P, Bens M, Vandewalle A, and Jentsch TJ.** Two highly homologous members
479 of the ClC chloride channel family in both rat and human kidney. *Proc Natl Acad Sci U S A* 91: 6943-
480 6947, 1994.

481 45. **Kobayashi K, Uchida S, Mizutani S, Sasaki S, and Marumo F.** Intrarenal and cellular
482 localization of ClC-K2 protein in the mouse kidney. *J Am Soc Nephrol* 12: 1327-1334, 2001.

483 46. **Kobayashi K, Uchida S, Okamura HO, Marumo F, and Sasaki S.** Human ClC-KB gene
484 promoter drives the EGFP expression in the specific distal nephron segments and inner ear. *J Am Soc*
485 *Nephrol* 13: 1992-1998, 2002.

486 47. **Kokubo Y, Iwai N, Tago N, Inamoto N, Okayama A, Yamawaki H, Naraba H, and Tomoike H.**
487 Association analysis between hypertension and CYBA, CLCNKB, and KCNMB1 functional
488 polymorphisms in the Japanese population--the Suita Study. *Circulation journal : official journal of*
489 *the Japanese Circulation Society* 69: 138-142, 2005.

490 48. **Konrad M, Vollmer M, Lemmink HH, van den Heuvel LP, Jeck N, Vargas-Poussou R, Lakings
491 A, Ruf R, Deschenes G, Antignac C, Guay-Woodford L, Knoers NV, Seyberth HW, Feldmann D, and
492 Hildebrandt F.** Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter
493 syndrome. *J Am Soc Nephrol* 11: 1449-1459, 2000.

494 49. **Kramer BK, Bergler T, Stoelcker B, and Waldegger S.** Mechanisms of Disease: the kidney-
495 specific chloride channels ClCKA and ClCKB, the Barttin subunit, and their clinical relevance. *Nat Clin*
496 *Pract Nephrol* 4: 38-46, 2008.

497 50. **L'Hoste S, Diakov A, Andrini O, Genete M, Pinelli L, Grand T, Keck M, Paulais M, Beck L,
498 Korbmacher C, Teulon J, and Lourdel S.** Characterization of the mouse ClC-K1/Barttin chloride
499 channel. *Biochim Biophys Acta* 1828: 2399-2409, 2013.

500 51. **Lee BH, Cho HY, Lee H, Han KH, Kang HG, Ha IS, Lee JH, Park YS, Shin JI, Lee DY, Kim SY, Choi
501 Y, and Cheong HI.** Genetic basis of Bartter syndrome in Korea. *Nephrol Dial Transplant* 27: 1516-
502 1521, 2012.

503 52. **Leviel F, Hubner CA, Houillier P, Morla L, El Moghrabi S, Brideau G, Hassan H, Parker MD,
504 Kurth I, Kougioumtzes A, Sinning A, Pech V, Riemondy KA, Miller RL, Hummler E, Shull GE, Aronson
505 PS, Doucet A, Wall SM, Chambrey R, and Eladari D.** The Na⁺-dependent chloride-bicarbonate
506 exchanger SLC4A8 mediates an electroneutral Na⁺ reabsorption process in the renal cortical
507 collecting ducts of mice. *J Clin Invest* 120: 1627-1635, 2010.

508 53. **Lin CM, Tsai JD, Lo YF, Yan MT, Yang SS, and Lin SH.** Chronic renal failure in a boy with classic
509 Bartter's syndrome due to a novel mutation in CLCNKB coding for the chloride channel. *Eur J Pediatr*
510 168: 1129-1133, 2009.

511 54. **Liu W, Morimoto T, Kondo Y, Iinuma K, Uchida S, Sasaki S, Marumo F, and Imai M.** Analysis
512 of NaCl transport in thin ascending limb of Henle's loop in ClC-K1 null mice. *Am J Physiol Renal*
513 *Physiol* 282: F451-457, 2002.

514 55. **Lourdel S, Grand T, Burgos J, Gonzalez W, Sepulveda FV, and Teulon J.** ClC-5 mutations
515 associated with Dent's disease: a major role of the dimer interface. *Pflugers Arch* 463: 247-256, 2012.

516 56. **Lourdel S, Paulais M, Marvao P, Nissant A, and Teulon J.** A chloride channel at the
517 basolateral membrane of the distal-convoluted tubule: a candidate CLC-K channel. *J Gen Physiol* 121:
518 287-300, 2003.

519 57. **Maduke M, Williams C, and Miller C.** Formation of CLC-0 chloride channels from separated
520 transmembrane and cytoplasmic domains. *Biochemistry* 37: 1315-1321, 1998.

521 58. **Markovic S, and Dutzler R.** The structure of the cytoplasmic domain of the chloride channel
522 CLC-Ka reveals a conserved interaction interface. *Structure* 15: 715-725, 2007.

523 59. **Martinez GQ, and Maduke M.** A cytoplasmic domain mutation in CLC-Kb affects long-distance
524 communication across the membrane. *PLoS One* 3: e2746, 2008.

525 60. **Marvao P, De Jesus Ferreira MC, Bailly C, Paulais M, Bens M, Guinamard R, Moreau R,**
526 **Vandewalle A, and Teulon J.** Cl⁻ absorption across the thick ascending limb is not altered in cystic
527 fibrosis mice. A role for a pseudo-CFTR Cl⁻ channel. *J Clin Invest* 102: 1986-1993, 1998.

528 61. **Matsumura Y, Uchida S, Kondo Y, Miyazaki H, Ko SB, Hayama A, Morimoto T, Liu W,**
529 **Arisawa M, Sasaki S, and Marumo F.** Overt nephrogenic diabetes insipidus in mice lacking the CLC-K1
530 chloride channel. *Nat Genet* 21: 95-98, 1999.

531 62. **Meyer S, and Dutzler R.** Crystal structure of the cytoplasmic domain of the chloride channel
532 CLC-0. *Structure* 14: 299-307, 2006.

533 63. **Meyer S, Savaresi S, Forster IC, and Dutzler R.** Nucleotide recognition by the cytoplasmic
534 domain of the human chloride transporter CLC-5. *Nat Struct Mol Biol* 14: 60-67, 2007.

535 64. **Niemeyer MI, Cid LP, Zuniga L, Catalan M, and Sepulveda FV.** A conserved pore-lining
536 glutamate as a voltage- and chloride-dependent gate in the CLC-2 chloride channel. *J Physiol* 553:
537 873-879, 2003.

538 65. **Niemeyer MI, Yusef YR, Cornejo I, Flores CA, Sepulveda FV, and Cid LP.** Functional
539 evaluation of human CLC-2 chloride channel mutations associated with idiopathic generalized
540 epilepsies. *Physiol Genomics* 19: 74-83, 2004.

541 66. **Nissant A, Lourdel S, Baillet S, Paulais M, Marvao P, Teulon J, and Imbert-Teboul M.**
542 Heterogeneous distribution of chloride channels along the distal convoluted tubule probed by single-
543 cell RT-PCR and patch clamp. *Am J Physiol Renal Physiol* 287: F1233-1243, 2004.

544 67. **Nissant A, Paulais M, Lachheb S, Lourdel S, and Teulon J.** Similar chloride channels in the
545 connecting tubule and cortical collecting duct of the mouse kidney. *Am J Physiol Renal Physiol* 290:
546 F1421-1429, 2006.

547 68. **Nozu K, Iijima K, Kanda K, Nakanishi K, Yoshikawa N, Satomura K, Kaito H, Hashimura Y,**
548 **Ninchoji T, Komatsu H, Kamei K, Miyashita R, Kugo M, Ohashi H, Yamazaki H, Mabe H, Otsubo A,**
549 **Igarashi T, and Matsuo M.** The pharmacological characteristics of molecular-based inherited salt-
550 losing tubulopathies. *J Clin Endocrinol Metab* 95: E511-518, 2010.

551 69. **Nozu K, Inagaki T, Fu XJ, Nozu Y, Kaito H, Kanda K, Sekine T, Igarashi T, Nakanishi K,**
552 **Yoshikawa N, Iijima K, and Matsuo M.** Molecular analysis of digenic inheritance in Bartter syndrome
553 with sensorineural deafness. *J Med Genet* 45: 182-186, 2008.

554 70. **Paulais M, and Teulon J.** cAMP-activated chloride channel in the basolateral membrane of
555 the thick ascending limb of the mouse kidney. *J Membr Biol* 113: 253-260, 1990.

556 71. **Pusch M.** Myotonia caused by mutations in the muscle chloride channel gene CLCN1. *Hum*
557 *Mutat* 19: 423-434, 2002.

558 72. **Pusch M.** Structural insights into chloride and proton-mediated gating of CLC chloride
559 channels. *Biochemistry* 43: 1135-1144, 2004.

560 73. **Pusch M, Steinmeyer K, Koch MC, and Jentsch TJ.** Mutations in dominant human myotonia
561 congenita drastically alter the voltage dependence of the CLC-1 chloride channel. *Neuron* 15: 1455-
562 1463, 1995.

563 74. **Riazuddin S, Anwar S, Fischer M, Ahmed ZM, Khan SY, Janssen AG, Zafar AU, Scholl U,**
564 **Husnain T, Belyantseva IA, Friedman PL, Friedman TB, and Fahlke C.** Molecular basis of DFNB73:
565 mutations of BSND can cause nonsyndromic deafness or Bartter syndrome. *Am J Hum Genet* 85: 273-
566 280, 2009.

75. **Robitaille P, Merouani A, He N, and Pei Y.** Bartter syndrome in two sisters with a novel mutation of the CLCNKB gene, one with deafness. *Eur J Pediatr* 170: 1209-1211, 2011.
76. **Rodriguez-Soriano J, Vallo A, Perez de Nanclares G, Bilbao JR, and Castano L.** A founder mutation in the CLCNKB gene causes Bartter syndrome type III in Spain. *Pediatr Nephrol* 20: 891-896, 2005.
77. **Schlingmann KP, Konrad M, Jeck N, Waldegger P, Reinalter SC, Holder M, Seyberth HW, and Waldegger S.** Salt wasting and deafness resulting from mutations in two chloride channels. *N Engl J Med* 350: 1314-1319, 2004.
78. **Schmidt-Rose T, and Jentsch TJ.** Reconstitution of functional voltage-gated chloride channels from complementary fragments of CLC-1. *J Biol Chem* 272: 20515-20521, 1997.
79. **Sepulveda FV, Pablo Cid L, Teulon J, and Niemeyer MI.** Molecular Aspects of Structure, Gating, and Physiology of pH-Sensitive Background K2P and Kir K+-Transport Channels. *Physiol Rev* 95: 179-217, 2015.
80. **Seyberth HW.** An improved terminology and classification of Bartter-like syndromes. *Nat Clin Pract Nephrol* 4: 560-567, 2008.
81. **Seyberth HW, and Schlingmann KP.** Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects. *Pediatr Nephrol* 26: 1789-1802, 2011.
82. **Sile S, Velez DR, Gillani NB, Narsia T, Moore JH, George AL, Jr., Vanoye CG, and Williams SM.** CLCNKB-T481S and essential hypertension in a Ghanaian population. *J Hypertens* 27: 298-304, 2009.
83. **Simon DB, Bindra RS, Mansfield TA, Nelson-Williams C, Mendonca E, Stone R, Schurman S, Nayir A, Alpay H, Bakaloglu A, Rodriguez-Soriano J, Morales JM, Sanjad SA, Taylor CM, Pilz D, Brem A, Trachtman H, Griswold W, Richard GA, John E, and Lifton RP.** Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. *Nat Genet* 17: 171-178, 1997.
84. **Simon DB, Karet FE, Hamdan JM, DiPietro A, Sanjad SA, and Lifton RP.** Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. *Nat Genet* 13: 183-188, 1996.
85. **Simon DB, Karet FE, Rodriguez-Soriano J, Hamdan JH, DiPietro A, Trachtman H, Sanjad SA, and Lifton RP.** Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK. *Nat Genet* 14: 152-156, 1996.
86. **Simon DB, and Lifton RP.** Mutations in Na(K)Cl transporters in Gitelman's and Bartter's syndromes. *Curr Opin Cell Biol* 10: 450-454, 1998.
87. **Speirs HJ, Wang WY, Benjafield AV, and Morris BJ.** No association with hypertension of CLCNKB and TNFRSF1B polymorphisms at a hypertension locus on chromosome 1p36. *J Hypertens* 23: 1491-1496, 2005.
88. **Staruschenko A.** Regulation of transport in the connecting tubule and cortical collecting duct. *Compr Physiol* 2: 1541-1584, 2012.
89. **Stauber T, Weinert S, and Jentsch TJ.** Cell biology and physiology of CLC chloride channels and transporters. *Compr Physiol* 2: 1701-1744, 2012.
90. **Takeuchi Y, Uchida S, Marumo F, and Sasaki S.** Cloning, tissue distribution, and intrarenal localization of CLC chloride channels in human kidney. *Kidney Int* 48: 1497-1503, 1995.
91. **Teulon J, Lourdel S, Nissant A, Paulais M, Guinamard R, Marvao P, and Imbert-Teboul M.** Exploration of the basolateral chloride channels in the renal tubule using. *Nephron Physiol* 99: p64-68, 2005.
92. **Tseng PY, Yu WP, Liu HY, Zhang XD, Zou X, and Chen TY.** Binding of ATP to the CBS domains in the C-terminal region of CLC-1. *J Gen Physiol* 137: 357-368, 2011.
93. **Uchida S.** In vivo role of CLC chloride channels in the kidney. *Am J Physiol Renal Physiol* 279: F802-808, 2000.
94. **Uchida S, and Sasaki S.** Function of chloride channels in the kidney. *Annu Rev Physiol* 67: 759-778, 2005.

95. **Uchida S, Sasaki S, Furukawa T, Hiraoka M, Imai T, Hirata Y, and Marumo F.** Molecular cloning of a chloride channel that is regulated by dehydration and expressed predominantly in kidney medulla. *J Biol Chem* 269: 19192, 1994.
96. **Uchida S, Sasaki S, Nitta K, Uchida K, Horita S, Nihei H, and Marumo F.** Localization and functional characterization of rat kidney-specific chloride channel, ClC-K1. *J Clin Invest* 95: 104-113, 1995.
97. **Unwin RJ, and Capasso G.** Bartter's and Gitelman's syndromes: their relationship to the actions of loop and thiazide diuretics. *Curr Opin Pharmacol* 6: 208-213, 2006.
98. **Urbanova M, Reiterova J, Stekrova J, Lnenicka P, and Rysava R.** DNA analysis of renal electrolyte transporter genes among patients suffering from Bartter and Gitelman syndromes: summary of mutation screening. *Folia biologica* 57: 65-73, 2011.
99. **Vargas-Poussou R, Dahan K, Kahila D, Venisse A, Riveira-Munoz E, Debaix H, Grisart B, Bridoux F, Unwin R, Moulin B, Haymann JP, Vantyghem MC, Rigotherier C, Dussol B, Godin M, Nivet H, Dubourg L, Tack I, Gimenez-Roqueplo AP, Houillier P, Blanchard A, Devuyst O, and Jeunemaitre X.** Spectrum of mutations in Gitelman syndrome. *J Am Soc Nephrol* 22: 693-703, 2011.
100. **Waldegger S, Jeck N, Barth P, Peters M, Vitzthum H, Wolf K, Kurtz A, Konrad M, and Seyberth HW.** Barttin increases surface expression and changes current properties of ClC-K channels. *Pflugers Arch* 444: 411-418, 2002.
101. **Waldegger S, and Jentsch TJ.** Functional and structural analysis of ClC-K chloride channels involved in renal disease. *J Biol Chem* 275: 24527-24533, 2000.
102. **Yu Y, Xu C, Pan X, Ren H, Wang W, Meng X, Huang F, and Chen N.** Identification and functional analysis of novel mutations of the CLCNKB gene in Chinese patients with classic Bartter syndrome. *Clin Genet* 77: 155-162, 2009.
103. **Zelikovic I, Szargel R, Hawash A, Labay V, Hatib I, Cohen N, and Nakhoul F.** A novel mutation in the chloride channel gene, CLCNKB, as a cause of Gitelman and Bartter syndromes. *Kidney Int* 63: 24-32, 2003.
104. **Zhang J, Sanguinetti MC, Kwiecinski H, and Ptacek LJ.** Mechanism of inverted activation of ClC-1 channels caused by a novel myotonia congenita mutation. *J Biol Chem* 275: 2999-3005, 2000.
105. **Zifarelli G, and Pusch M.** Intracellular regulation of human ClC-5 by adenine nucleotides. *EMBO reports* 10: 1111-1116, 2009.

FIGURE LEGEND

Figure 1. Localization of the two ClC-K channels along the rodent renal tubule and ion transport systems in various parts of the distal nephron. A) Localization of ClC-K1 (blue) and ClC-K2 (orange) along the nephron. The localization is based on RTPCR on rat isolated renal segments (49, 66, 100), immunochemistry (19, 45) and patch-clamp studies on the mouse renal tubule (50, 56, 66, 67, 70). The distribution pattern remains incomplete: 1) in the absence of a dedicated patch-clamp study, it is not known whether ClC-K1 is present in the α intercalated cells together with ClC-K2; 2) Although, ClC-K1 messenger RNA is present in the late distal tubule and the collecting duct, ClC-K1 has not been detected in these two renal segments using the patch-clamp technique (50, 56, 66, 67, 70). ClC-K1 might be active only during specific physiologic conditions. B) NaCl absorption in the thick ascending limb involves NKCC2 $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransport in the apical membrane and ClC-K2 and ClC-K1 in the basolateral membrane. C) NaCl absorption in the distal convoluted tubule involves NCC $\text{Na}^+\text{-Cl}^-$ cotransport in the basolateral membrane and ClC-K2 in the basolateral membrane. D) The β intercalated cells (β ic) absorb NaCl (18) and the α intercalated cells (α ic) secrete protons. NaCl absorption involves the Pendrin $\text{Cl}^-/\text{HCO}_3^-$ exchanger and NDCBE $\text{Na}^+\text{-driven Cl}^-/\text{HCO}_3^-$ exchanger in the apical membrane, and AE4 $\text{Cl}^-/\text{HCO}_3^-$ exchanger and ClC-K2 in the basolateral membrane. The KCC4 $\text{K}^+\text{-Cl}^-$ cotransporter might also allow Cl^- exit. The α intercalated cells secrete H^+ by the operation of the V-type H^+ ATPase in the apical membrane and AE1 $\text{Cl}^-/\text{HCO}_3^-$ exchanger in the basolateral membrane. ClC-K2 with or without ClC-K1 is present in the basolateral membrane and might optimize the turnover rate of the exchanger.

Figure 2. Homology model of the ClC-Kb Cl^- channel based on the Eukaryotic ClC of *Cyanidioschyzon merolae* (PDB id. 3ORG) that includes the cystathione- β -syntase domains. A side-view of the dimeric structure is shown in cartoon representation, where the membrane is delimited by dotted lines. The monomers are colored orange and blue. The permeation pore in the left-hand side monomer is shown as a continuous series of white spheres, and amino acids participating in the

selectivity filter are shown in sticks in both monomers. On the extracellular side, green and purple spheres show the putative location of Ca^{2+} and H^+ binding sites, respectively, as inferred from comparison with prokaryotic *Escherichia coli* (PDB id. 1KPK) and eukaryotic *Cyanidioschyzon merolae* CLCs using Multalin software for multiple sequence alignments (15), plus manual adjustments. The location of the binding sites slightly depends on the homology model, especially for the Ca^{2+} binding site. As a result, the number of spheres is larger than the number of involved amino acids. Pymol software (The PyMOL Molecular Graphics System, Version 1.7, Schrödinger, LLC) was used to render figure.

Figure 3. Mutations in the CLC-Kb Cl^- channel associated with Bartter disease. The location of mutations is illustrated on a topological model of CLC-Kb where rectangles represent α -helices. The plasma membrane is not shown; the lower part of the model is intracellular, the upper part extracellular. The letters indicate the corresponding α -helices and CBS1 and CBS2 the two cystathione- β -syntase domains. The α -helices participating in the selectivity filter, those interacting with Barttin and those located at the dimer interface are colored in green, yellow and purple, respectively. Each symbol gives the position and the type of a single mutation, the number referring to mutations in Table 1.

Table 1. *CLCNKB* mutations and corresponding changes in amino acid sequence of the ClC-Kb chloride channel.

Mutat ion numb er	Nucleotide change	Amino acid change	Protein domain	Remaining current	Sensitivity to H ⁺ and Ca ²⁺	Surface expression	Total ClC- Kb protein
----------------------------	-------------------	-------------------------	-------------------	----------------------	---	-----------------------	--------------------------

1	c.88C>T (102)	R30X	α helix A					
2	c.216C>A (6)	A61D	α helix B					
3	c.226C>T (68)	R76X	α helix B					
4	c.229G>C (75)	A77P	α helix B					
5	c.229G>A (48)	A77T	α helix B					
6	c.242T>C (36)	L81P	α helix B	35% (43)	= (43)	30% (43)	= (43)	
7	c.274C>T (43)	R92W	α helix C	67% (43)	= (43)	85% (43)	= (43)	
8	c.343A>C (43)	T115P	α helix C	18% (3)				
9	c.358G>C (3)	G120R	C-D linker	60% (3)	= (3)			
10	c.359G>T (51)	G120V	C-D linker					
11	c.371C>T (48, 83)	P124L	α helix D	0% (101); 45% (19); 73% (3) 27% (3)	Altered (3)	= (101)	= (101)	
12	c.451T>C (83)	L139P	D-E linker					
13	c.480T>A (6)	V149E	α helix E					
14	c.490G>T (2)	G164C	E-F linker					
15	c.508G>A (3)	V170M	α helix F	60% (3)	Altered (3)	60% (3)		
16	c.610G>A (76, 83)	A204T	α helix G	25% (19); 0% (101)		= (101)	= (77)	
17	c.629C>T (102)	A210V	α helix G	~50% (102)	= (102)			
18	c.647C>T (51)	P216L	G-H linker					
19	c.708C>A (3)	Y236X	H-I linker					
20	c.725C>A(5)	A242E	α helix I					
21	c.736G>C (43)	G246R	α helix I	10%* (43)		None (43)	↓ (43)	
22	c.887G>A (99)	G296D	α helix J					
23	c.927G>A (48)	S297R	α helix J					
24	908A>C (98)	Q303P	α helix J					
25	c.1004T>C (13)	L335P	α helix K					
26	c.1045T>C (83)	S337F	α helix K					
27	c.1046G>A (83)	A349D	K-L linker	0% (101); 10% (19)		↓ (101)	↓ (101)	
28	c.1052G>C (43)	R351P	K-L linker	63% (43)	= (43)	65%(43)	= (43)	
29	c.1051C>T (102)	R351W	K-L linker	~60% (102)	Ca ²⁺ altered (102)			
30	c.1107T>A (48)	H357Q	α helix L					
31	c.1172G>A (68)	A391X	L-M linker					
32	c.1270G>A (51)	G424R	M-N linker					
33	c.1270G>A (43)	G424E	M-N linker	10%* (43)		None (43)	↓ (43)	
34	c.1294T>C (83)	Y432H	α helix N	~20% (101)		↓ (101)	= (101)	
35	c.1309G>A (51)	G437C	α helix N					
36	c.1312C>T (83)	R438C	α helix N	0% (101); 10%* (43)		↓ (101)	= (101)	
37	c.1313G>A (48, 103)	R438H	α helix N	18%* (43)		None (43)	↓ (43)	
38	c.1316T>C (43)	L439P	α helix N	15%* (43)		None (43)	↓ (43)	
39	c.1325A>G (29)	E442G	α helix N					
40	c.1340T>C (99)	I447T	N-O linker					
41	c.1409G>A (53)	G470E	α helix O					
42	c.1537C>T (83)	Q513X	α helix Q					
43	c.1648G>C 31)	R538P	Linker R- CBS1	25% (19)	Ca ²⁺ altered (59)			
44	c.1714A>T 31)	K560M	CBS1	50% (19)				
45	c.1685C>T (27)	M562T	CBS1					
46	c.1753T>A (48)	S573Y	CBS1					
47	c.1732G>A (27)	K578E	CBS1					
48	c.1783C>T (6)	R595X	CBS1					
49	c.1830G>A (26, 51)	W610X	CBS1					
50	c.1877G>A (99)	C626Y	CBS2					

698

699 *Residual current not statistically different from measured current in noninjected oocytes (36).

700 Numbers between parentheses indicate references.

701

Figure 1







Figure 2




Figure 3

